A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Clinical trial NCT06043323 · RECRUITING
Trial details
- NCT number
- NCT06043323
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-08
- Primary completion
- 2026-09-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.